Premium
Hepatitis B vaccination of 113 hemophiliacs: Lower antibody response in anti‐LAV/HTLV‐III‐positive patients
Author(s) -
Zanetti A. R.,
Mannucci P. M.,
Tanzi E.,
Moroni G. A.,
De Paschale M.,
Morfini M.,
Carnelli V.,
Tirindelli M. C.,
De Biasi R.,
Ciavarella N.,
De Rosa V.,
Rodeghiero F.,
Colombo M.
Publication year - 1986
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830230406
Subject(s) - medicine , booster dose , titer , vaccination , hepatitis b vaccine , hepatitis b , virology , immunology , antibody , hepatitis a vaccine , hepatitis b virus , viral disease , hepatitis , hepatitis a , virus , hbsag
Abstract One‐hundred thirteen adults and children with hemophilia or other congenital bleeding disorders were vaccinated against the hepatitis B virus. Each patient was given three subcutaneous injections of the vaccine at monthly intervals and then a fourth booster dose 14 months after the first. The vaccine was highly immunogenic, since 111 of 113 patients (98%) produced anti‐HBs (10 mlU/ml or more). After the first three vaccine doses and after the booster dose, ten anti‐LAV/HTLV‐III‐positive hemophiliacs produced anti‐HBs but had a lower average titer than anti‐LAV/HTLV‐III‐negative hemophiliacs. Of the 23 patients treated with concentrates in the 15 month postvaccination period only, none acquired HBV infection. Of the 50 patients treated with concentrates also in the 6 month prevaccination period, one developed hepatitis B. In summary, the vaccine was highly immunogenic in both children and adults with hemophilia; anti‐LAV/HTLV‐III‐positive patients responded to the vaccine, but the average anti‐HBs response was lower; no case of hepatitis B occurred in patients treated with concentrates only in the postvaccination period.